Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,441 stopped studies mapped to Leukemia and descendants · 87% state a reason
Over the 1,441 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04282174 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies(2019-KOE-001) | Phase 2 | withdrawn | Feb 24, 2020 | Baptist Health South Florida | Study was split into two new studies before the first participant was enrolled. | Enrollment / accrual |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory… | Phase 1 | terminated | Jul 14, 2017 | AstraZeneca | Sponsor Decision | Sponsor / business decision |
| NCT04425655 | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed… | Phase 2 | terminated | Jun 11, 2020 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT01440179 | SAR3419 in Acute Lymphoblastic Leukemia(MYRALL) | Phase 2 | terminated | Sep 26, 2011 | Sanofi | The study is stopped due to very modest activity compared to competitors | Other (stated, no rule matched) |
| NCT03549351 | Evaluation of Measurable Residual Disease in Patients With Acute Myeloid Leukemia as…(PERDAM) | — | terminated | Jun 8, 2018 | University Hospital Heidelberg | Study turned out no longer feasible | Other (stated, no rule matched) |
| NCT04272203 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose… | Phase 1 | terminated | Feb 17, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Phase 1 | terminated | Oct 20, 2014 | Aptose Biosciences Inc. | Drug manufacturing process and procedure review | Drug supply |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and… | Phase 1 / Phase 2 | terminated | Dec 20, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT04406207 | Endogenous Retroviruses in Acute Myeloid Leukemia(ERVAL) | — | withdrawn | May 28, 2020 | Hospices Civils de Lyon | COVID-19 | COVID-19 / pandemic |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or…(MT-3724NHL001) | Phase 1 / Phase 2 | terminated | Feb 11, 2015 | Molecular Templates, Inc. | Sponsor decision following clinical hold | Sponsor / business decision |
| NCT04006496 | AML Expressive Writing | N/A | terminated | Jul 5, 2019 | Duke University | Recruitment issues due to COVID-19 pandemic. | COVID-19 / pandemic |
| NCT03760666 | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | terminated | Nov 30, 2018 | Clear Creek Bio, Inc. | No efficacy observed, COVID-19 caused sites to shut down | COVID-19 / pandemic |
| NCT02773732 | Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute… | Phase 1 / Phase 2 | terminated | May 16, 2016 | University of Florida | slow enrollment | Enrollment / accrual |
| NCT04807478 | Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis… | — | withdrawn | Mar 19, 2021 | Fresenius Kabi | New study protocol under development | Other (stated, no rule matched) |
| NCT04665115 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With… | Phase 2 | withdrawn | Dec 11, 2020 | Academic and Community Cancer Research United | Permanently closed 11/19/201. The widespread availability of COVID vaccination, the projected… | COVID-19 / pandemic |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2012 | Roswell Park Cancer Institute | Sponsor wanted study rewritten | Other (stated, no rule matched) |
| NCT03207256 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in… | Phase 2 | terminated | Jul 2, 2017 | TG Therapeutics, Inc. | Strategic/Business Decision | Sponsor / business decision |
| NCT03768310 | CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic… | Phase 1 | withdrawn | Dec 7, 2018 | Baylor College of Medicine | We decided to move on to another product and as a result will not be moving forward with this study. | Other (stated, no rule matched) |
| NCT01241786 | Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for…(VZCLLPI0146) | Phase 2 | terminated | Nov 16, 2010 | Hackensack Meridian Health | The study was closed early due to poor accrual | Enrollment / accrual |
| NCT05001451 | Study of GDX012 in Patients With MRD Positive AML | Phase 1 | terminated | Aug 12, 2021 | GammaDelta Therapeutics Limited | This was a business decision to discontinue this clinical trial. The decision is not related to the… | Safety / toxicity |
| NCT03988205 | Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for… | Phase 4 | terminated | Jun 17, 2019 | Medical College of Wisconsin | Low accrual | Enrollment / accrual |
| NCT01773395 | GVAX vs. Placebo for MDS/AML After Allo HSCT | Phase 2 | terminated | Jan 23, 2013 | Dana-Farber Cancer Institute | Recommendation by the Data and Safety Monitoring Board due to efficacy concerns | Safety / toxicity |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jul 13, 2012 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT00961142 | Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity…(CD3/CD19 Haplo) | Phase 2 | terminated | Aug 18, 2009 | University Hospital Tuebingen | slow recruitment | Enrollment / accrual |
| NCT04006847 | Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid… | Phase 1 / Phase 2 | terminated | Jul 5, 2019 | Milton S. Hershey Medical Center | Product complaint | Other (stated, no rule matched) |
| NCT04093505 | Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients…(GnG) | Phase 3 | terminated | Sep 18, 2019 | University Hospital Heidelberg | Study turned out no longer feasible. End of Recruitment: 25.5.2022 | Enrollment / accrual |
| NCT01177540 | Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in… | Phase 2 | terminated | Aug 9, 2010 | Eisai Inc. | The study was terminated early due to enrollment difficulties and the futility of observing… | Efficacy / futility |
| NCT01982175 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia(CLL004) | Phase 2 | suspended | Nov 13, 2013 | Shanghai Zhangjiang Biotechnology Limited Company | recruiting difficulties | Enrollment / accrual |
| NCT03850535 | A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine… | Phase 1 / Phase 2 | terminated | Feb 21, 2019 | Hoffmann-La Roche | Sponsor's decision to terminate the study after Phase 1; will not proceed with Phase 2. | Sponsor / business decision |
| NCT04326439 | AflacLL1901 (CHOA-AML) | Phase 2 | terminated | Mar 30, 2020 | Emory University | Due to unforeseen circumstances, the study team was limited in enrolling patients on this trial;… | Enrollment / accrual |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic…(HERKULES-4) | Phase 1 / Phase 2 | withdrawn | Mar 15, 2022 | Erasca, Inc. | Sponsor decision. | Sponsor / business decision |
| NCT04655391 | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute… | Phase 1 | withdrawn | Dec 7, 2020 | City of Hope Medical Center | Drug availability | Drug supply |
| NCT03063203 | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Feb 24, 2017 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT04676243 | Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in…(Q-SOC) | Phase 3 | withdrawn | Dec 19, 2020 | University Hospital Heidelberg | Study turned out no longer feasible | Other (stated, no rule matched) |
| NCT02999854 | Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation…(HATCY) | Phase 3 | terminated | Dec 21, 2016 | Kiadis Pharma | Insufficient efficacy, terminated by Sponsor | Efficacy / futility |
| NCT03594955 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid… | Phase 1 / Phase 2 | terminated | Jul 20, 2018 | Sanofi | Sponsor decision | Sponsor / business decision |
| NCT03552029 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia… | Phase 1 | terminated | Jun 11, 2018 | Daiichi Sankyo | This study was terminated based on a business decision by the Sponsor. | Sponsor / business decision |
| NCT04264806 | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in… | Phase 2 | withdrawn | Feb 11, 2020 | Janssen Research & Development, LLC | The cusatuzumab MDS strategy is under revision | Sponsor / business decision |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | Phase 1 | terminated | Apr 14, 2021 | Eden BioCell Ltd. | CAR-T manufacturing technology can not meet the dose requirement for clinical patients. | Drug supply |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | Phase 1 | terminated | Dec 7, 2012 | TG Therapeutics, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT02043587 | Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic… | Phase 2 | terminated | Jan 23, 2014 | University of California, San Diego | Original investigator for the trial has left | Investigator |
| NCT00968864 | T-cell Depleted Alternative Donor Transplantation | Phase 2 | terminated | Aug 31, 2009 | Wake Forest University Health Sciences | Sponsor/ PI leaving institution, no plans to continue this research at this time | Other (stated, no rule matched) |
| NCT02927938 | Leukemia Stem Cell Detection in Acute Myeloid Leukemia | Phase 3 | terminated | Oct 7, 2016 | Wake Forest University Health Sciences | Study terminated 7/23/2019 due to limited participation and testing challenges. | Other (stated, no rule matched) |
| NCT03600909 | A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients… | Phase 2 | terminated | Jul 26, 2018 | Memorial Sloan Kettering Cancer Center | Accrual has been slow | Enrollment / accrual |
| NCT04155840 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic… | Phase 2 | terminated | Nov 7, 2019 | University of Washington | Terminated due to low accrual | Enrollment / accrual |
| NCT04858594 | Study of Periodontitis and Blood Stream Infection in AML Patients Receiving Chemotherapy | — | terminated | Apr 26, 2021 | Masonic Cancer Center, University of Minnesota | PI left and research was stopped | Investigator |
| NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as… | Phase 1 | terminated | Jul 14, 2017 | AstraZeneca | strategic decision | Sponsor / business decision |
| NCT04660045 | Early Intervention With Acalabrutinib in Patients With High Risk CLL | Phase 2 | withdrawn | Dec 9, 2020 | Weill Medical College of Cornell University | Company supplying drug/funding ceased support. | Funding |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Phase 1 | terminated | Aug 24, 2010 | South Plains Oncology Consortium | drug supply | Drug supply |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 27, 2022source: clinicaltrials